Our results demonstrate that the use of ex vivo generated DCs loaded with a mixture of allogeneic melanoma cell lines is safe and it elicits immune response against tumor Ags, shown by: i) an increased DTH; ii) an increase of anti-Melan A/MART-1 and anti-gp100 lymphocytes; iii) activation of lymphocytes directed to as yet unspecified Ags. The gene discussed is PMEL; the disease is neoplasm.